OIG Sides With Manufacturers On Calculating Sales To Retail Pharmacies For Final AMP Rule
This article was originally published in The Pink Sheet Daily
Executive Summary
In a report on manufacturers’ average manufacturer price practices, the HHS Office of Inspector General says the industry’s current use of “presumptive inclusion” to determine when drug sales are made through a retail community pharmacy should be retained, contrary to what CMS proposed in its draft AMP rule.